Substance P prevented cell death in dopaminergic neurons exposed to a Parkinson's-inducing toxin by reducing calcium overload, oxidative stress, and mitochondrial damage through NK-1 receptor activation.
NK-1 receptor mediatedAll neuroprotective effects of substance P were completely abolished by the NK-1 receptor antagonist SR140333B, confirming the specific mechanism
What the researchers found
Substance P (specifically the selective NK-1 agonist [Sar9, Met(O2)11]-SP) protected MES23.5 dopaminergic cells from MPP+-induced toxicity through multiple mechanisms:
- Prevented MPP+-triggered apoptosis (programmed cell death)
- Decreased MPP+-induced calcium (Ca2+) influx into cells
- Reduced caspase-3 reactivity (a key enzyme in the cell death cascade)
- Lowered reactive oxygen species (ROS) production
- Preserved mitochondrial membrane potential (preventing mitochondrial collapse)
- Inhibited phosphorylation of JNK and p38 MAP kinase (stress-activated signaling pathways)
All protective effects were abolished when the NK-1 receptor antagonist SR140333B was co-administered, confirming that substance P's neuroprotection is mediated specifically through NK-1 receptors.
Why it matters
Parkinson's disease currently has no treatments that stop or slow neuronal death — all existing drugs only manage symptoms. If substance P genuinely protects dopamine neurons, it could represent a neuroprotective strategy. The finding that the protection works through a specific receptor (NK-1) makes it potentially targetable with drugs, though the complexity is that NK-1 receptor antagonists are being developed for other conditions, creating a therapeutic paradox.
How the study worked
MES23.5 dopaminergic cells (a hybrid cell line of rat mesencephalic neurons) were treated with MPP+ (1-methyl-4-phenylpyridinium) to induce Parkinson's-like toxicity. Cells were pre-treated with substance P ([Sar9, Met(O2)11]-SP) with or without the NK-1 receptor antagonist SR140333B. Researchers measured cell viability, DNA fragmentation, calcium influx, caspase-3 activity, reactive oxygen species levels, mitochondrial membrane potential, and phosphorylation of JNK and p38 MAPK signaling pathways.
What this study cannot tell us
This is an in vitro study using a single cell line (MES23.5), which does not replicate the complex environment of the living brain with its multiple cell types, blood-brain barrier, and immune interactions. The MPP+ model, while widely used, represents only one mechanism of dopaminergic cell death in Parkinson's disease. Specific concentrations of substance P and MPP+ used are not detailed in the abstract. No dose-response relationship is described. The findings have not been validated in animal models of Parkinson's disease.
How to read the evidence
This is a basic science in vitro study using a single cell line. While the mechanistic dissection is thorough (multiple endpoints, receptor antagonist confirmation), cell line results have limited predictive value for human disease. The evidence is preliminary and requires in vivo validation.
When this study was published
Published in 2015, this study contributes to an ongoing debate about substance P's role in neurodegeneration. The neuropeptide's dual nature — pro-inflammatory in some contexts, neuroprotective in others — continues to be investigated.
The bigger picture
Substance P is traditionally known as a pain transmitter and inflammatory mediator, making it seem like an unlikely neuroprotectant. This study adds to a growing body of evidence suggesting substance P has context-dependent roles — harmful in inflammation but potentially protective in neurodegeneration. This creates an interesting therapeutic tension, since NK-1 receptor antagonists are being developed for pain and depression, while this work suggests NK-1 activation might be beneficial for Parkinson's. Understanding when and where substance P is helpful versus harmful is a key question in neuropeptide biology.
Questions still open
- Does substance P protect dopamine neurons in animal models of Parkinson's disease, or only in isolated cell cultures?
- How can the neuroprotective effects of NK-1 receptor activation be harnessed without triggering the pain and inflammatory effects of substance P?
- Do Parkinson's patients have reduced substance P levels in their brains, and does this correlate with disease severity?
Common questions
What is substance P and why might it protect brain cells?
Could substance P be used as a treatment for Parkinson's disease?
Read the original research
Substance P prevents 1-methyl-4-phenylpyridinium-induced cytotoxicity through inhibition of apoptosis via neurokinin-1 receptors in MES23.5 cells.
Molecular medicine reports, 12(6), 8085-92
Citation
Wang, Shuang-Yan; Chen, Lei; Xue, Yan; Xia, Yu-Jun. (2015). Substance P prevents 1-methyl-4-phenylpyridinium-induced cytotoxicity through inhibition of apoptosis via neurokinin-1 receptors in MES23.5 cells.. Molecular medicine reports, 12(6), 8085-92. https://doi.org/10.3892/mmr.2015.4464